PORT WASHINGTON, N.Y., July 29, 2015 - Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification technologies, today announced that Pall shareholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated May 12, 2015 (the “Merger Agreement”), by and among Pall, Danaher Corporation (NYSE:DHR) and Pentagon Merger Sub, Inc. at a special meeting of shareholders held on July 28, 2015 at the Company’s headquarters in Port Washington, NY.

 

At the Special Meeting, 87,395,064 million shares were voted in favor of the proposal to adopt the Merger Agreement, which represents approximately 81.79% of Pall’s outstanding shares.

 

Under the terms of the Merger Agreement, each share of common stock issued and outstanding immediately prior to the effective time of the merger of Pentagon Merger Sub with and into Pall (the “Merger”) will be canceled and automatically converted into the right to receive $127.20 in cash, without interest.

 

The Merger is subject to certain additional customary closing conditions, including receipt of regulatory approvals in several jurisdictions. We continue to expect the Merger to close by the end of calendar 2015.

 

A full description of the proposed Merger is included in the proxy statement for the special meeting, which is available at http://investors.pall.com.

 

About Pall Corporation

 

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Follow us on Twitter @PallCorporation or visit www.pall.com.

 

Forward-Looking Statements

 

This press release may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are those that use terms such as “may,” “will,” “expect,” “believe,” “intend,” “should,” “could,” “anticipate,” “estimate,” “forecast,” “project,” “plan,” “predict,” “potential,” and similar expressions. Forward-looking statements contained in this and other written and oral reports are based on management’s assumptions and assessments in light of past experience and trends, current conditions, expected future developments and other relevant factors.

 

The Company’s forward-looking statements are subject to risks and uncertainties and are not guarantees of future performance, and actual results, developments and business decisions may differ materially from those envisaged by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; the outcome of any legal proceedings that may be instituted against the Company related to the Merger Agreement; the inability to complete the transaction due to the failure to satisfy other conditions to completion of the transaction, including the receipt of all regulatory approvals related to the transaction; the disruption of management’s attention from the Company’s ongoing business operations due to the transaction; the effect of the announcement of the transaction on the Company’s relationships with its customers, operating results and business generally; the effects of local and national economic, credit and capital market conditions; and other risk factors described in the Company’s Annual Report on Form 10-K for the year ended July 31, 2014 filed with the Securities and Exchange Commission. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The statements made herein are made as of the date of this disclosure and the Company undertakes no obligation to update them, whether as a result of new information, future developments or otherwise.

 

View source version on businesswire.com: http://www.businesswire.com/news/home/20150729005286/en/

Media Contact:
Pall Corporation
Jim Conenello
Director, Investor Relations & Corporate Communications
(516) 801-9871


Investor Contact:
Pall Corporation
R. Brent Jones
Interim Chief Financial Officer
(516) 801-9871

More Pall Corporation Press Releases
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
March 1, 2019 - Pall Corporation Obtains FAA PMA Approval and extends its Advanced Cabin Air Filters (A-CAF) product line to Boeing.
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing